These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37688806)

  • 1. COVID-19 vaccine safety in Scotland - background rates of adverse events of special interest.
    Cullen LA; Grange Z; Antal K; Waugh L; Alsina MS; Gibbons CL; MacDonald LE; Robertson C; Cameron JC; Stockton D; O'Leary MC
    Public Health; 2023 Nov; 224():1-7. PubMed ID: 37688806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Moll K; Lufkin B; Fingar KR; Ke Zhou C; Tworkoski E; Shi C; Hobbi S; Hu M; Sheng M; McCarty J; Shangguan S; Burrell T; Chillarige Y; Beers J; Saunders-Hastings P; Muthuri S; Edwards K; Black S; Kelman J; Reich C; Amend KL; Djibo DA; Beachler D; Ogilvie RP; Secora A; McMahill-Walraven CN; Seeger JD; Lloyd P; Thompson D; Dimova R; MaCurdy T; Obidi J; Anderson S; Forshee R; Wong HL; Shoaibi A
    Vaccine; 2023 Jan; 41(2):333-353. PubMed ID: 36404170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Phillips A; Jiang Y; Walsh D; Andrews N; Artama M; Clothier H; Cullen L; Deng L; Escolano S; Gentile A; Gidding G; Giglio N; Junker T; Huang W; Janjua N; Kwong J; Li J; Nasreen S; Naus M; Naveed Z; Pillsbury A; Stowe J; Vo T; Buttery J; Petousis-Harris H; Black S; Hviid A
    Vaccine; 2023 Oct; 41(42):6227-6238. PubMed ID: 37673715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study.
    Kang W; Shami JJP; Yan VKC; Ye X; Blais JE; Li X; Lee VHF; Chui CSL; Lai FTT; Wan EYF; Wong CKH; Wong ICK; Chan EW
    J Hematol Oncol; 2022 May; 15(1):66. PubMed ID: 35590336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Pillsbury A; Phillips A; Deng L; Quinn H; Macartney K; Gidding H
    Vaccine; 2023 May; 41(22):3422-3428. PubMed ID: 37088604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Adverse Events and Delirium after COVID-19 Vaccination in Patients Living with Dementia.
    Cheung ECL; Leung MTY; Chen K; Wan EYF; Li X; Lai FTT; Wong CKH; Qin XS; Chan EW; Lau KK; Luo H; Lin CC; Wong ICK; Chui CSL
    J Am Med Dir Assoc; 2023 Jun; 24(6):892-900.e12. PubMed ID: 37156470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era.
    Shah SA; Robertson C; Rudan I; Murray JL; McCowan C; Grange Z; Buelo A; Sullivan C; Simpson CR; Ritchie LD; Sheikh A
    J Glob Health; 2022; 12():05008. PubMed ID: 35356660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of incomplete COVID-19 vaccine schedule among adults in Scotland: Two retrospective cohort analyses of the primary schedule and third dose.
    Morrison K; Cullen L; James AB; Chua V; Sullivan C; Robertson C; Carruthers J; Wood R; Jeffrey K; MacDonald C; Shah SA; Rudan I; Simpson CR; McCowan C; Vittal Katikireddi S; Grange Z; Ritchie L; Sheikh A
    Vaccine; 2023 Sep; 41(40):5863-5876. PubMed ID: 37598025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.
    Li X; Ostropolets A; Makadia R; Shoaibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard MA; Ryan PB; Hripcsak G; Prieto-Alhambra D
    BMJ; 2021 Jun; 373():n1435. PubMed ID: 35727911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
    Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study.
    Nasreen S; Calzavara AJ; Sundaram ME; MacDonald SE; Righolt CH; Pai M; Field TS; Zhou LW; Wilson SE; Kwong JC
    BMJ Open; 2021 Dec; 11(12):e052019. PubMed ID: 34921078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.
    Agrawal U; Katikireddi SV; McCowan C; Mulholland RH; Azcoaga-Lorenzo A; Amele S; Fagbamigbe AF; Vasileiou E; Grange Z; Shi T; Kerr S; Moore E; Murray JLK; Shah SA; Ritchie L; O'Reilly D; Stock SJ; Beggs J; Chuter A; Torabi F; Akbari A; Bedston S; McMenamin J; Wood R; Tang RSM; de Lusignan S; Hobbs FDR; Woolhouse M; Simpson CR; Robertson C; Sheikh A
    Lancet Respir Med; 2021 Dec; 9(12):1439-1449. PubMed ID: 34599903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Background incidence rates of health outcomes of interest for COVID-19 vaccine safety monitoring in a US population: a claims database analysis.
    Banga S; Khromava A; Serradell L; Chabanon AL; Pan C; Estevez I; Schilsky S; Kreisberg H
    BMJ Open; 2024 Jul; 14(7):e083947. PubMed ID: 38991681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
    Kaur U; Fatima Z; Maheshwari K; Sahni V; Dehade A; Kl A; Yadav AK; Kansal S; Jaisawal V; Chakrabarti SS
    Drug Saf; 2023 Jun; 46(6):553-563. PubMed ID: 37133805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Covid-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection.
    Lai FTT; Huang L; Peng K; Li X; Chui CSL; Wan EYF; Wong CKH; Chan EWY; Hung IFN; Wong ICK
    J Intern Med; 2022 Jun; 291(6):864-869. PubMed ID: 35043503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
    Katikireddi SV; Cerqueira-Silva T; Vasileiou E; Robertson C; Amele S; Pan J; Taylor B; Boaventura V; Werneck GL; Flores-Ortiz R; Agrawal U; Docherty AB; McCowan C; McMenamin J; Moore E; Ritchie LD; Rudan I; Shah SA; Shi T; Simpson CR; Barreto ML; Oliveira VA; Barral-Netto M; Sheikh A
    Lancet; 2022 Jan; 399(10319):25-35. PubMed ID: 34942103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No increased incidence of venous thrombosis or pulmonary embolism after SARS-CoV-2 vaccination in Germany.
    Tanislav C; Rosenbauer J; Zingel R; Kostev K
    Public Health; 2022 Jun; 207():14-18. PubMed ID: 35461122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.